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GRAPHICAL ABSTRACT
Background: Cat allergy in human subjects is usually caused by
the major cat allergen Fel d 1 and is found in approximately
10% of the Western population. Currently, there is no efficient
and safe therapy for cat allergy available. Allergic patients
usually try to avoid cats or treat their allergy symptoms.
Objective: We developed a new strategy to treat Fel d 1–induced
allergy in human subjects by immunizing cats against their own
major allergen, Fel d 1.
Methods: A conjugate vaccine consisting of recombinant Fel d 1
and a virus-like particle derived from the cucumber mosaic virus
containing the tetanus toxin–derived universal T-cell epitope
tt830-843 (CuMVTT) was used to immunize cats. A first
tolerability and immunogenicity study, including a boost
injection, was conducted by using the Fel-CuMVTT vaccine
alone or in combination with an adjuvant.
Results: The vaccine was well tolerated and had no overt toxic
effect. All cats induced a strong and sustained specific IgG
antibody response. The induced anti–Fel d 1 antibodies were of
high affinity and exhibited a strong neutralization ability
tested both in vitro and in vivo. A reduction in the endogenous
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allergen level and a reduced allergenicity of tear samples, were
observed.
Conclusion: Vaccination of cats with Fel-CuMVTT induces
neutralizing antibodies and might result in reduced symptoms
of allergic cat owners. Both human subjects and animals could
profit from this treatment because allergic cat owners would
reduce their risk of developing chronic diseases, such as asthma,
and become more tolerant of their cats, which therefore could
stay in the households and not need to be relinquished to animal
shelters. (J Allergy Clin Immunol 2019;nnn:nnn-nnn.)
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A large number of biological drugs have been developed in the
last 30 years for humans; however, they are only now on the
horizon of veterinary medicine. Validated targets for humans are
now being used to develop mAb therapies for pets to treat cancer
and chronic diseases, such as anti-CD52 or anti-CD20 in patients
with lymphoma and anti–IL-31 or anti–nerve growth factor in
patients with pruritus and chronic pain, respectively. Upon
application, mAbs have an immediate effect and mediate symp-
tom relief. However, with respect to their half-life, monthly
injections may be necessary to ensure efficacy, with a cost
estimation of $5,000 to $50,000 per year in human subjects. In
addition, somemAb therapies result in treatment failure by losing
their effectiveness because of induction of anti-drug antibodies,
and both local and systemic side effects can occur.
An alternative approach is the development of vaccines. Active
immunization induces a polyclonal response that increases the
possibility of efficacy by recognizing several epitopes and
requires 1 to 2 repeated injections per year, with a cost estimate
of $200 to $1000. However, the challenge of vaccination is to
overcome self-tolerance to induce a strong and sustained antibody
response to achieve efficacy in patients with chronic diseases and
cancer. Our new conjugate vaccine technology facilitates this by
using an immunologically improved plant virus-like particle
(VLP) as carrier derived from a modified cucumber mosaic virus
containing the tetanus toxin–derived universal T-cell epitope
tt830-843 (CuMVTT).
1
Compared with viruses, VLPs form icosahedral structures
consisting of the viral coat protein (CP) but do not carry genetic
information and therefore have no capacity to replicate and only
share the viral structural and geometric features. VLPs exhibit a
highly repetitive and organized surface, which represents a
pathogen-associated structural pattern shared by most viruses
but not extracellular host proteins.2 Furthermore, the CuMVTT
VLPs used here carry RNA from the bacterial production strain,3,4
which is a ligand for Toll-like receptor 7 and 8 and is a pathogen
associated-molecular pattern. Thus our VLPs carry both
pathogen-associated structural patterns and pathogen-associated
molecular patterns, which renders them a suitable carrier platform
for antigens by linking them to the surfaces of the VLPs.5-7
Recently, we have shown that vaccines based on CuMVTT are
able to induce antibodies against IL-31 that treat atopic dermatitis
in dogs, as well as antibodies against IL-5 that treat insect-bite hy-
persensitivity in horses.8,9 Here we extend this platform to immu-
nize cats against their own allergen, Fel d 1.
Cats are found in about 25% of households in Western
countries, and allergy to cats is found in approximately 10% of
the human population.10 In addition to Fel d 1–specific IgE
antibodies driving type I hypersensitivity, specific TH cells also
contribute to the pathology of the allergic reaction in human sub-
jects, which is known as type IV hypersensitivity, causing recruit-
ment of additional inflammatory cells, such as eosinophils, to
mucosal surfaces and other tissues.11,12 The severity of symptoms
ranges from relatively mild rhinitis and conjunctivitis to poten-
tially life-threatening asthmatic exacerbation. Affected patients
usually treat their cat allergy symptomatically with antihista-
mines and corticosteroids, which have limited efficacy, consider-
able side effects, or both. A second approach is specific
immunotherapy involving repeated injections for a minimum of
2 to 3 years with increasing dosages aiming at the induction of
IgG antibodies and activation of TH1 cells, regulatory T cells,
or both.11,13 In recent decades, great efforts have been made to
characterize and standardize cat allergens for immuno-
therapy.14-16 Moreover, various routes of application, such as
the subcutaneous, sublingual, or intralymphatic, were tested for
safety and efficacy in mice and human subjects.14,17,18 Although
some very promising results have been observed, none of these
therapies have been approved for the market thus far and thus
are not available for the treatment of cat allergy in human
subjects.
Practical approaches to reduce allergen load in the environment
of allergic patients include washing cats, keeping them out of the
bedroom, or use of different filter devices, such as high-efficiency
particulate air filters or temperature-controlled laminar airflows.
However, these efforts are often not implemented long term
because there is a lack of commitment and the costs for filters and
filtering devices are high and hardly covered by health insurance
companies. As a consequence of ineffective therapies, cat owners
frequently have to give their cats away to animal shelters,19 where
their fate is often sealed because the shelters often have no choice
but to euthanize them.
Within the One Health paradigm, we propose to reduce or
prevent cat allergy in human subjects by immunizing cats against
their own allergen. Several feline allergens have been identi-
fied,20-23 but the singular importance of Fel d 1 as the major cat
allergen has been emphasized in numerous studies showing that
approximately 90% of patients with cat allergy have IgE anti-
bodies to this potent allergen.24 Fel d 1 is constitutively produced
by salivary, skin, lacrimal, and perianal glands.25-29 Male cats
exhibit higher levels of the protein and, on castration, reach
similar levels compared with female cats.30 Although some
Abbreviations used
CP: Coat protein
CRL: Charles River Laboratories
CuMVTT: Cucumber mosaic virus containing the tetanus
toxin–derived universal T-cell epitope tt830-843
HRP: Horseradish peroxidase
IMAC: Immobilized metal ion affinity chromatography
LC/ESI/MS/MS: Liquid chromatography–electrospray ionization–
tandem mass spectrometry
OD50: Reciprocal of the dilution at which half of the OD
maximum measured at saturation is reached
SMPH: Succinimidyl-6-(b-maleimidopropionamido)
hexanoate
STT: Schirmer tear test
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function in pheromone binding31 and pelt conditioning has been
suggested, the biological function of Fel d 1 remains uncertain.
Avaccine targeting Fel d 1 in cats will affect the allergic response
at the first possible point of intervention by inducing Fel d 1–spe-
cific antibodies in the animal. These antibodies will bind endog-
enous Fel d 1 and thus decrease or neutralize its allergenic effect
in human subjects.
Here we show that vaccination of cats with Fel d 1 displayed on
CuMVTT-VLPs results in high-titer and long-lasting antibody re-
sponses. Antibodies bound to the solvent-exposed surface of Fel
d 1 and were able to neutralize the allergen both in vitro and in-
vivo. Hence allergic cat ownersmay be treated bymeans of immu-
nization of their cats against Fel d 1.
METHODS
Ethics statement
The study involving human blood from allergic patients was approved by
the KEK (Zurich, Switzerland) ethics committee and was conducted under
license number ZU-Basophils-001. The immunization studies in cats were
performed at Charles River Laboratories (CRL) in Den Bosch, The
Netherlands, or Glenamoy, Ireland, and were either approved by the Dutch
Animal Welfare Officer and the Ethical Committee (DEC 14-112) or by the
Irish Animal Welfare Office (experimental DOH license no. B100/4500).
Study procedures were performed in accordance with guidelines of the
European Medicines Agency/Committee for Proprietary Medicinal Products
(CPMP/SWP/465/95, June 1998) and in accordance with European Union
(Protection of Animals used for Scientific Purposes) Regulation 2012
(Statutory Instrument no. 543 of 2012). All mouse experiments were
conducted in accordancewith ethical principles and guidelines of the Cantonal
Veterinary Office, Zurich, Switzerland.
Mice
BALB/c mice were purchased from Harlan (Horst, The Netherlands) and
held under enhanced hygienic conditions (Optimaler Hygienischer Bereich in
German). Experiments were conducted at the facility in Schlieren, Switzerland,
run by the Laboratory Animal Services Center and were in accordance to
guidelines approved by the Cantonal Veterinary Office, Zurich, Switzerland.
Cats
Cat studies conducted at CRL (Den Bosch, The Netherlands) included
domestic shorthair cats obtained from Liberty Research (Waverly, NY) and
acclimatized for 3 weeks. Intact, nonneutered, multiparous, and naive female
cats at the age of 1 to 3 years were enrolled in the study. The cat study
conducted at CRL, Glenamoy, Ireland, included cats from the CRL Ireland cat
colony. They were intact, nonneutered, multiparous, and naive female cats
aged 8 to 55 months that had been acclimatized for 7 days.
Cat immunization and sample collection
Two groups of 3 cats received 100 mg of Fel-CuMTTT formulated in 1 mL
of PBS 3 times at 3-week intervals in alternating hind limbs intramuscularly.
One group of cats received vaccine formulated with adjuvant (15 mg of
saponin per cat per dose).
Meta-analysis of the anti–Fel d 1 IgG response included 54 cats of 4
different cat studies. The studies were conducted to investigate various
aspects, such as immunogenicity, tolerability, comparison of vaccine batches,
and optimal dose finding. Three male and 51 female cats received 3 injections
on days 0, 21, and 42 of different doses (3 mg [n 5 5], 10 mg [n 5 5], 30 mg
[n 5 5], 100 mg [n5 29, including male cats], 300 mg [n 5 5], and 1000 mg
[n 5 5]) administered subcutaneously.
Serum samples were collected at study days 0, 21, 42, 58, 71, and 85 from
all cats and on days 203, 252, 268, and 282 from cats 2, 3, and 5. Blood samples
were drawn from the vena jugularis by using serum vacutainers (Greiner Bio-
One GmbH, Frickenhausen, Germany). Serum samples were stored at2208C
until analysis.
Tear samples were collected from cats on study days 0, 42, and 84 by using
Schirmer tear test (STT) stripes. The STT stripes were placed in the
ventrolateral conjunctival fornix for approximately 1 minute. Cats were
conscious and tolerated the procedure well. STT stripes were weighed to
determine the collected amount of tear fluid.
Size exclusion of recombinant Fel d 1
Pure Fel d 1 solution after immobilized metal ion affinity chromatography
(IMAC) purification was characterized by means of size exclusion with a
Superdex 75-pg column (GE Healthcare, Chicago, Ill) and an €AKTA purifier.
The analysis was performed with PBS buffer, the storage buffer of recombi-
nant Fel d 1 solution.
Analysis of Fel d 1 by using capture ELISA
ELISAplates were coated overnight at 48Cwith an anti–Fel d 1mouse IgG1
(clone 6F9 A4 H1; INDOOR Biotechnologies, Charlottesville, Va) as 1 mg/
mL in 0.1 mol/L NaHCO3 pH 9.6 buffer and blocked with SuperBlock
(Thermo Fisher Scientific, Waltham, Mass) for 2 hours at room temperature.
Solutions of 1000 ng/mL natural or recombinant Fel d 1 were prepared and
applied to plates, serial diluted, and incubated for 2 hours at room temperature.
Bound Fel d 1 protein reacted with a biotinylated mouse IgG1 anti–Fel d 1
mAb 3E4 C4 C10 (INDOOR Biotechnologies) in a 1:1000 dilution in 2%
BSA/PBS-Tween for 1 hour at room temperature and further incubated with
streptavidin–horseradish peroxidase (HRP) conjugate for 30 minutes at
room temperature for detection. Bound enzyme was detected by means of re-
action with o-phenylenediamine (OPD; Honeywell, Seelze, Germany) for
7 minutes and stopped by addition of sulfuric acid. PBS-Tween was used as
washing buffer. ODs were read with a Tecan Spark 10MELISA reader (Tecan,
Zurich, Switzerland) at 450 nm.
Basophil activation test with blood from patients
with cat allergy
The Flow CAST Basophil Activation Test (B€UHLMANN Laboratories,
Sch€oenbuch, Switzerland) was used to determine degranulation of blood-
derived basophils by following the producer’s instructions. Briefly,
stimulation buffer was mixed with EDTA-treated whole blood from a
patient with Fel d 1 allergy. An unstimulated blood sample or incubation
with a positive (antibody against FcεRI) or unspecific (N-formyl-me-
thionyl-leucyl-phenylalanine, peptide) control were included in the exper-
iment. Serial dilutions of natural and recombinant Fel d 1 were tested for
their ability to activate blood-derived basophils. Staining dye containing
anti-CCR3 mAb labeled with phycoerythrin and anti-CD63 mAb labeled
with fluorescein isothiocyanate were added to the blood samples and
incubated at 378C for 25 minutes. Erythrocytes were lysed, and samples
were centrifuged and washed. After centrifugation, cell pellets were
resuspended in stimulation buffer and acquired by using a flow cytometer
(FACS Fortessa; BD, Franklin Lakes, NJ). Samples were analyzed with
FACSDiva software. The percentage of CD63 expression on CCR31 baso-
phils was determined.
Production of Fel-CuMVTT vaccine
The sequence encoding a fusion of chains 1 and 2 of Fel d 1 was cloned into
the plasmid pET42. A histidine tag for purification purposes and a small linker
sequence, including a cysteine residue for chemical linkage, were added to the
C-terminus of chain 2. The plasmid pET42 was transformed into Escherichia
coli C2566I (New England Biolabs, Ipswich, Mass), and soluble protein
expression was performed at 208C for 20 hours induced by isopropyl b-D-
1-thiogalactopyranoside. Cells were sonicated. Supernatants after centrifuga-
tion containing Fel d 1 were collected and purified by using IMAC. After
elution with an increased imidazole concentration (250 mmol/L), Fel d 1
was dialyzed against PBS overnight at 48C.
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Expression and purification of CuMVTT are described elsewhere.
1 Briefly,
the sequence of the monomer CP of CuMVTTwas cloned into the pET28a(1)
vector and transformed in E coli C2566 cells. Recombinant VLP expression
was performed for 20 hours induced by isopropyl b-D-1-
thiogalactopyranoside. Cell pellets were sonicated, and insoluble proteins
and cell debris were cleared by means of centrifugation. CuMVTT-CP was pu-
rified by using ammonium sulfate precipitation and ultracentrifugation with a
sucrose gradient (20% to 60% sucrose).
Lysine residues of the CuMVTTwere reacted with a 7.53 molar excess of
the crosslinker succinimidyl-6-(b-maleimidopropionamido)hexanoate
(SMPH) for 60 minutes at room temperature to produce the Fel-CuMVTT vac-
cine. Unreacted SMPH was removed using a PD10 column. Before coupling
of Fel d 1 protein with the derivatized CuMVTT particles, Fel d 1 was treated
with a 103 molar excess of Tris(2-carboxyethyl)phosphine hydrochloride
(TCEP*HCl), a mild reducing agent, to provide access to the cysteine. Deriv-
atized CuMVTT reacted with 23 molar excess of Fel d 1 for 3 hours at room
temperature. The vaccine was stored at 48C until used for vaccination.
Detection of specific IgG antibodies in cat serum by
means of ELISA (indirect format)
ELISA plates were coated overnight at 48C with 1 mg/mL natural Fel d 1
(INDOOR Biotechnology) or 1 mg/mL recombinant Fel d 1 (produced as
described herein) in PBS and blocked with SuperBlock (Pierce, Thermo
Fisher Scientific) for 2 hours at room temperature. CuMVTT (1 mg/mL) was
coated in PBS on ELISA plates overnight at 48C and blocked with SuperBlock
(Pierce) for 2 hours at room temperature to detect anti-VLP IgG. Plates were
incubated with serial-diluted study sera for 2 hours at room temperature.
Bound cat antibodies were detected with the secondary goat anti-cat IgG
HRP (Bethyl Laboratories, Montgomery, Tex) for 1 hour at room temperature.
Bound enzymewas detected by means of reaction with OPD (Fluka) for 7 mi-
nutes and stopped through addition of sulfuric acid (5% H2SO4). PBS-Tween
was used as a washing buffer. ODs were recorded with a Tecan Spark 10M
ELISA reader at 450 nm. ELISA titers are given as the reciprocals of the di-
lutions needed to achieve 50% of the OD of the maximal signal measured at
saturation (OD50). Geometric mean titers were calculated from all cats of
each group.
Detection of specific IgG antibodies in cat serum by
means of ELISA (capture format)
ELISA plates were coated overnight at 48C with 1 mg/mL anti–Fel d 1
human IgG4 G078
32 in PBS and blocked with SuperBlock (Pierce, Thermo
Fisher Scientific) for 2 hours at room temperature. Plates were incubated
with either natural (INDOOR Biotechnology) or recombinant Fel d 1 (pro-
duced as described herein) in PBS at a concentration of 1 mg/mL for 1 hour
at room temperature. Serial-diluted serum samples were applied onto plates
for 2 hours at room temperature. The secondary goat anti-cat IgGHRP (Bethyl
Laboratories) was added for 1 hour at room temperature. Bound enzyme was
detected by means of reaction with OPD (Fluka) for 7 minutes and stopped by
addition of sulfuric acid. PBS-Tween was used as washing buffer. ODs were
analyzed by using a Tecan Spark 10M ELISA reader at 450 nm. ELISA titers
are given as the reciprocals of the dilutions needed to achieve OD50. Geomet-
ric mean titers of each time point were calculated from all animals against nat-
ural Fel d 1 or recombinant Fel d 1.
Linear epitope mapping of Fel d 1–specific
antibodies of cat sera
The epitope mapping analysis of cat sera was performed by PEPperPRINT
GmbH (Heidelberg, Germany). The sequence of recombinant Fel d 1 protein
was elongated by using neutral GSGSGSG linkers at the C- and N-terminus.
The elongated antigen sequence was translated into 15-amino-acid peptides
with a peptide-peptide overlap of 14 amino acids. The resulting peptide
microarrays contained 187 different peptides printed in duplicate (374 peptide
spots) and were framed by additional HA (YPYDVPDYAG) and Flag
(DYKDDDDKAS) control peptides. The microarray was blocked with
Rockland blocking buffer MB-070 in PBS-Tween. Dilutions of cat sera
(1:1000) obtained from the boosting study from days 252 and 312 were
applied to the array for 16 hours at 48C shaking at 140 rpm. Bound antibodies
were detected by using goat anti-cat IgG (Fc) DyLight680 (dilution 1:5000)
for 45 minutes at room temperature. Arrays were scanned with the LI-COR
Odyssey Imaging System (LI-COR, Lincoln, Neb). The structure was created
by using PyMol with the Protein Data Bank identifier 2EJN.31
Surface plasmon resonance
Surface plasmon resonancemeasurements were performedwith the BIAcore
X100 device (GE Healthcare). HBS-EP1 (10 mmol/L HEPES [pH 7.4],
150 mmol/L NaCl, 3 mmol/L EDTA, and 0.005% surfactant P20) was used as
the running buffer (flow rate, 10 mL/min). By using an amine coupling kit,
monomeric recombinant Fel d 1 produced in our laboratory was coupled to flow
cell 2 of a CM5 sensor chip to an immobilization level of 1300 RU (GE
Healthcare). Flow cell 1 remained uncoated and served as a control for
unspecific binding to the sensor chip surface.Diluted sera from cats 2, 3, and 5 of
the immunogenicity study after 2 immunizations obtained on day 43 were then
injected for 2minutes on both flow cells at constant buffer flow. The dissociation
rate was measured for another 2 minutes at constant buffer flow. For control
purposes, the monoclonal anti–Fel d 1 IgG1 G078 at a concentration of 50 nmol/
L and diluted naive cat serum were injected into the coated chip.
Generation of mAbs against recombinant Fel d 1
By using a mammalian cell display,33 isolation and generation of 3 mAbs
recognizing the nonoverlapping epitopes A044, F127, and G078 on Fel d 1
were recently described.32
Neutralization ELISA
ELISA plates were coated with 1 mg/mL anti–Fel d 1 mouse IgG1 (clone
6F9 A4H1; INDOORBiotechnologies) in 0.1 mol/L NaHCO3 (pH 9.6) buffer
overnight at 48C. Plates were blocked with SuperBlock (Thermo Fisher Scien-
tific) for 2 hours at room temperature. Recombinant Fel d 1 at a concentration
of 100 ng/mL was incubated for 30 minutes at room temperature either alone,
with diluted cat serum samples (1:2 diluted), or with anti–Fel d 1 human IgG4
A044 at a concentration of 100 ng/mL; applied to ELISA plates; and serial
diluted. Bound Fel d 1 protein reacted with a biotinylated mouse IgG1 anti–
Fel d 1 mAb (3E4 C4 C10; INDOOR Biotechnologies) at a 1:1000 dilution
in 2% BSA PBS-Tween for 1 hour at room temperature and was further incu-
bated with HRP-SA for 30 minutes at room temperature for detection. Bound
enzyme was detected by means of reaction with OPD (Fluka) for 7 minutes
and was stopped by addition of sulfuric acid. PBS-Tween was used as washing
buffer. ODs were read with a Tecan Spark 10M ELISA reader at 450 nm.
Ear prick tests in mice
BALB/c mice at 8 weeks of age received 5 mg each of the anti–Fel d 1
mouse IgE clones A044 and F127 intravenously to sensitize them to Fel d 1.
A couple of hours later, mice received 150 mL of cat serum obtained from an
immunogenicity study. Preimmune (day 0) and postimmune (day 63) cat sera
were collected from 2 cats that had received 3 injections of 100 mg of Fel-
CuMVTT in a 3-week interval on study days 1, 21, and 42. Before transfer into
mice, preimmune and postimmune sera were purified by protein A and G (GE
Healthcare). One group of mice did not receive cat serum and served as
controls.
After 24 hours of cat sera transfer, mice received 200mL of Evan’s blue dye
(0.5% wt/vol in PBS). After an hour, anesthetized mice received 10 mg in a
volume of 20mL of recombinant Fel d 1 placed on one ear and pricked through
the ear skin by using a lancet. After 45 minutes, mice were killed, and ears
were removed to extract the dye as a degree of extravasation. Ears were mixed
with 150 mL of 1 mol/L KOH and incubated at 378C overnight. Then 150 mL
ofH3PO4 (5% in acetone) was added, and the solutionwas cleared bymeans of
centrifugation. OD values at 595 nm of supernatants were recorded.
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Quantification of Fel d 1 in tears by using ELISA
ELISA plates were coated overnight at 48Cwith an anti–Fel d 1mouse IgG1
(clone 6F9 A4 H1; INDOOR Biotechnologies) at 1 mg/mL in 0.1 mol/L
NaHCO3 (pH 9.6) buffer and blocked with SuperBlock (Thermo) for 2 hours
at room temperature. A 1:10 dilution of standard allergen solution was applied
to each ELISA plate and 1:2 serial diluted for quantification. Solutions of tear
extracts were applied to plates, serial diluted, and incubated for 2 hours at
room temperature. Bound Fel d 1 allergen in tear extracts and standard
allergen solution reacted with a biotinylated mouse IgG1 anti–Fel d 1 mAb
(clone 3E4 C4 C10; INDOOR Biotechnologies) in a 1:1000 dilution in 2%
BSA/PBS-Tween for 1 hours at room temperature and was further incubated
with HRP-SA for 30 minutes at room temperature for detection. Bound
enzyme was detected by means of reaction with OPD (Fluka) for 7 minutes
and stopped by addition of sulfuric acid. PBS-Tween was used as washing
buffer. The linear range of the standard allergen solution was used for Fel
d 1 quantification in cat tear extracts.
Fel d 1 identification and quantification using mass
spectrometry
Quantification of Fel d 1 in tear extracts from cats was performed by using
liquid chromatography–electrospray ionization–tandem mass spectrometry
(LC/ESI/MS/MS). A unique peptide, ALPVVLENAR, of the major cat allergen
Fel d 1 located on chain 1 (http://www.uniprot.org/uniprot/P30438) was identi-
fied and used for comparison with a synthesized heavy peptide version with a
C-terminal (R[13C6; 15N4]). Tear extracts (75 mL) of individual cats were
precipitated bymixingwith an equal volume of 20% trichloroacetic acid. Pellets
were washed twicewith cold acetone and dissolved in 10 mmol/LTris-HCl and
2 mmol/L CaCl2 (pH 8.2) containing 4 ng/mL trypsin (Roche, Mannheim, Ger-
many) and 9.6 fmol/mL of the (R[13C6; 15N4])-labeled Fel d 1 peptide. Micro-
wave (Model Discover; CEM, Matthews, NC)–assisted digestion was
performed at 5W for 30 minutes at 608C. Samples were dried by means of vac-
uum centrifugation, dissolved in 0.1% formic acid (Romil, Cambridge, United
Kingdom), and analyzed on a nanoAcquity UPLC (Waters, Milford, Mass) con-
nected to a Q Exactive Mass Spectrometer (Thermo Scientific) equipped with a
Digital PicoView source (New Objective, Woburn, Mass). Peptides were trap-
ped on a Symmetry C18 trap column (5 mm, 180 mm 3 20 mm; Waters) and
separated on a BEH300 C18 column (1.7 mm, 75 mm 3 150 mm; Waters) at
a flow rate of 250 nL/min by using a gradient from 1% solvent B (0.1% formic
acid in acetonitrile; Romil)/99% solventA (0.1% formic acid inwater; Romil) to
40% solvent B/60% solvent A within 90 minutes. Mass spectrometer settings
were as follows: precursor scan range, 350 to 1500 m/z; resolution, 70,000;
maximum injection time, 100 ms; and threshold, 3 3 106. The fragment ion
scan range was 200 to 2000 m/z, resolution was 35,000, maximum injection
time was 120 ms, and the threshold was 1 3 105.
Raw data files from the mass spectrometer of the Fel d 1 light and heavy
peptides were loaded to a software for label-free quantification (Progenesis QI
for Proteomics; Waters), and automatic aligning was performed. From each
Progenesis peptide ion (default sensitivity in peak picking), a maximum of the
top 5 tandem mass spectra were exported by using the charge deconvolution
and deisotoping option and amaximum number of 200 peaks perMS/MS. The
Mascot generic file (.mgf) was searched with Mascot Server version 2.5.3
(www.matrixscience.com) by using the parameters of 10 ppm for precursor
ion mass tolerance and 0.04 Da for fragment ion tolerance. Trypsin was
used as the protein-cleaving enzyme, allowing 2 missed cleavages. Carbami-
domethylation of cysteine was specified as a fixed modification, and oxida-
tions of methionine and heavy arginine (Arg10) were selected as variable
modifications.
A forward and reversed cat database (downloaded onMarch 18, 2015, from
UniProt) concatenated to 260 known mass spectrometric contaminants was
searched to evaluate the false discovery rate by using the target-decoy
strategy.34
FIG 1. Expression of vaccine intermediates Fel d 1 protein and CuMVTT-VLP and Fel-CuMVTT vaccine anal-
ysis. A, Profile of SEC analysis of recombinantly expressed Fel d 1 after purification with PBS. B, Capture
ELISA (INDOOR Biotechnology) showing OD values (450 nm) of a series of different concentrations of re-
combinant (rec) and natural (nat) Fel d 1. C, Basophil Activation Test. Upregulation of the degranulation
marker CD63 of blood-derived basophils from patients with cat allergy on incubation with either recombi-
nant or natural Fel d 1 protein was measured. Controls included unstimulated, anti-FcεRI antibody stimula-
tion, and N-formyl-methionyl-leucyl-phenylalanine (fMLP). D, Electron microscopic image of purified
CuMVTT-VLP. E, SDS-PAGE analysis (NuPAGE 4-12% Bis-Tris) under denaturing and reducing conditions
of the Fel-CuMVTT vaccine. Lane 1, Molecular weight marker (Invitrogen SeeBlue Pre-stained); lane 2,
CuMVTT-CP, approximately 24.5-kDa monomer, 5 mg; lane 3, CuMVTT-CP crosslinked with SMPH, 5 mg;
lane 4, Fel d 1, 20 kDa, 5 mg; and lane 5, Fel-CuMVTT vaccine, 5 mg of VLP or 8.6 mg of total protein.
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Mascot results were exported as XML, and results were imported in
Progenesis. Focusing on the abundance of the heavy and light ‘‘ALPVVLE-
NAR’’ peptide (where the concentration of the heavy peptide was a priori
known) allowed us to estimate the natural (light) concentration of the Fel
d 1 peptide for each sample.
Statistical analysis
All data were analyzed using GraphPad Prism software (GraphPad
Software, La Jolla, Calif), and significance (P < .05) was obtained by using
paired or unpaired t tests.
RESULTS
Generation of a conjugate vaccine targeting Fel d 1
Natural Fel d 1 is a 35- to 39-kDa tetrameric glycoprotein
containing 10% to 20% N-linked carbohydrates. It is formed by 2
noncovalently linked heterodimers consisting of 2 chains derived
from separate genes. Chain 1 consists of 70 amino acids, and
chain 2 consists of 92 amino acids, the latter existing in several
truncated forms (78, 85, and 90 amino acids). Three intermolec-
ular disulfide bridges link chain 1 with chain 2, leading to an
antiparallel orientation of both chains.26,35-37 It was previously
FIG 2. Immunization of cats with Fel-CuMVTT vaccine. A, Immunization scheme describing the immuniza-
tion and subsequent boosting study. B-H, Antibody titers determined by using an indirect ELISA are re-
ported as OD50 values. B, Serum IgG antibody titers against natural Fel d 1 protein of cats 1 to 3 (group
1). C, Serum IgG antibody titers against CuMVTT-VLP of cats 1 to 3 (group 1). D, Serum IgG antibody titers
against natural Fel d 1 protein of cats 4 to 6 (group 2). E, Serum IgG antibody titers against CuMVTT-VLP for
cats 4 to 6 (group 2). F, Serum IgG antibody titers against natural Fel d 1 protein of cats 2, 3, and 5.G, Serum
IgG antibody titers against CuMVTT-VLP of cats 2, 3, and 5. H, Anti–Fel d 1 IgG in cat sera of 54 cats obtained
from 4 different cat studies. Significance was determined by using a 2-tailed paired t test comparing all 54
cats before immune serum with first vaccination, first with second vaccination, and second with third
vaccination.
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shown that Fel d 1 can be recombinantly expressed as a geneti-
cally linked heterodimer with a conserved antigen authenticity38
that can be conjugated to VLPs.1,39
We used the same strategy herein. Fel d 1 protein was
recombinantly expressed comprising chain 1 (71 amino acids)
fused to the N-terminus of chain 2 (92 amino acids) by a 15-
amino-acid linker sequence with modifications at the C–terminus
containing a cysteine for coupling to VLPs. Soluble recombinant
Fel d 1 protein was expressed in E coli and purified by using
IMAC. A pure protein was obtained with the majority of mono-
mers, corresponding to the natural dimer caused by the linker
and dimers corresponding to natural tetramers (Fig 1, A).
A commercial capture ELISA using mAbs generated against nat-
ural Fel d 1 was performed to test the antigenic authenticity
(Fig 1,B).We also tested the ability of recombinant Fel d 1 to acti-
vate basophils in blood from patients with cat allergy who carry
Fel d 1–specific IgE bound to FcεRI by using a basophil activation
assay.40 In comparisonwith natural Fel d 1 protein, recombinantly
expressed Fel d 1 was similarly recognized by mAbs in the cap-
ture ELISA (Fig 1,B) and could equally stimulate basophils of pa-
tients with cat allergy analyzed by upregulation of the exclusive
degranulation marker CD63 (Fig 1, C).
Generation and characterization of the CuMVTT-derived VLPs
is described in detail elsewhere.1 It consists of the CP of the
CuMV expressed in E coli. The monomers spontaneously
assemble into VLPs enclosing RNA from E coli during the pro-
duction process. The icosahedral VLPs have a diameter of
approximately 30 nm and consist of 180 copies of CP monomer
with a size of 24.5 kDa that leads to a molecular weight of
4430 kDa for 1 VLP (Fig 1, D and E). The free cysteine in the re-
combinantly expressed Fel d 1 protein was coupled to lysine res-
idues on the surfaces of VLPs through the crosslinker SMPH to
generate a vaccine against Fel d 1. SDS-PAGE analysis of the
coupling reaction shows a primary coupling band that
corresponds to 1VLPmonomer (24.5 kDa) linked to 1 Fel d 1 pro-
tein (20 kDa) with a size of 44.5 kDa (Fig 1, E). The coupling
leads to a coupling efficiency of 8% that corresponds to 14 mol-
ecules of Fel d 1 bound to 1 VLP.
Induction of Fel d 1–specific antibodies upon
immunization of cats with Fel-CuMVTT
The new vaccine candidate Fel-CuMVTT was tested in
naive female domestic shorthair cats in an immunogenicity
study (Fig 2, A). Before immunization, there were no signifi-
cant anti–Fel d 1 or anti-CuMVTT IgG levels detectable (Fig
2, B-E). Fel d 1–specific IgG was detected on day 22 after a
single immunization, and levels increased further after the
second immunization on day 22. The third immunization on
day 43 maintained the anti–Fel d 1 IgG response at a high level
(Fig 2, B and D).
The anti-CuMVTT IgG response showed similar kinetics as the
anti–Fel d 1 response (Fig 2, C and E). The first immunization
significantly increased the anti-CuMVTT IgG response from base-
line. Although the second immunization further increased the
anti-CuMVTT IgG response, the third vaccination maintained
the specific IgG response (until day 252) on a high level (Fig 2,
C andE). Co-administration of a saponin-based adjuvant had little
effect on the magnitude and kinetics of the antibody response (Fig
2, B-E).
The objective of the booster injection in week 36 was to
determinewhether late administration of Fel-CuMVTT resulted in
maintaining or boosting Fel d 1– and CuMVTT-specific antibody
levels. Upon booster injection, anti–Fel d 1 IgG and anti-CuMVTT
IgG levels in all 3 immunized cats increased to similar levels seen
after the first 3 immunizations (Fig 2, F and G). Of note, the spe-
cific antibody titers for Fel d 1 and CuMVTT-VLP after the first 3
FIG 3. Characterization of antibodies induced by Fel-CuMVTT vaccination in cats. A and B,Mean OD50 anti-
body titers measured against natural (nat) and recombinant (rec) Fel d 1 by using a capture ELISA (Fig 3, A)
or indirect ELISA (Fig 3, B; n 5 3). C, Interaction of serum antibodies from immunized cats with Fel d 1 an-
tigen measured by using surface plasmon resonance. D, Three-dimensional structure of Fel d 1 tetramer (or
homodimer) exhibiting the identified epitopes of antibodies found in cat sera upon Fel-CuMVTT vaccination
by using linear epitopemapping. Green denotes chain 1 and blue denotes chain 2 of the Fel d 1 heterodimer.
The location of the consensus epitope is shown in red, and the minor epitope is shown in orange.
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immunizations only marginally decreased and stayed at a high
level.
A meta-analysis of the anti–Fel d 1 IgG response involving 3
male and 51 female cats from 4 different studies further
demonstrates the strong immunogenicity and tolerability of the
Fel-CuMVTT vaccine (Fig 2, H).
Antibodies induced by Fel-CuMVTT vaccination in
cats are highly specific
We characterized the cat anti–Fel d 1 IgG response induced by
vaccination by comparing capture (Fig 3, A) and indirect (Fig 3,
B) ELISA formats performed with natural Fel d 1 extracted
from fur washes and our recombinantly produced Fel d 1. Anti-
bodies induced in cats after immunization with Fel-CuMVTT
recognized coated and captured natural and recombinant versions
of Fel d 1 (Fig 3, A and B). Furthermore, the overall titers and
binding kinetics were similar, and the method of antigen display
did not influence the binding of cat IgG to antigen, indicating
good recognition of natural Fel d 1.
The kinetics of binding and dissociation of serum antibodies
with Fel d 1 antigen were analyzed by means of surface plasmon
resonance with BIAcore. Preimmune and postimmune (day 43)
sera were analyzed for binding to monomeric recombinant Fel
d 1, which corresponds to the natural heterodimer Fel d 1 (Fig 3,
C). Preimmune cat serum did not bind to Fel d 1, whereas serum
after 2 injections with Fel-CuMVTT vaccine showed a strong
interaction with the antigen. The binding phase of a polyclonal
serum in BIAcore experiments reflects the antibody quality and
quantity able to bind to immobilized antigen. The BIAcore signal
occurred more rapidly for cats 3 and 5 than for cat 2, which is
consistent with the anti–Fel d 1 ELISA results in Fig 2, B and
C. In contrast to the binding phase, the dissociation phase reflects
the average off-rate of the antibodies and is independent of anti-
body concentrations. Therefore it is interesting to note that an
anti–Fel d 1 mAb (clone G078) with a high affinity and low off-
rate32,41 showed a similar dissociation curve as the cat sera, in-
dicting similar off-rates for the various antibodies.
To further characterize cat antibody binding, we sought to
identify their epitope specificity. A linear peptide library encom-
passing recombinant Fel d 1 was constructed. The library
comprised 187 peptides, each 15 amino acids in length, with a
14-amino-acid overlap to the preceding peptide. The peptide
microarrays were incubated with immune sera, and peptide
binding of cat IgG was identified by means of immunostaining.
A strong and clear IgG response to a common epitope was found.
This epitope had the consensus motif ENALSVLDK located on
chain 1. In addition, a minor epitope with the sequence
TGTPDEYVE, also located on chain 1, was identified. Neither
epitope was recognized by preimmune sera, but both were
recognized by postimmune sera from all cats. The consensus
and minor epitopes were mapped onto the 3-dimensional
structure of the Fel d 1 tetramer that corresponds to the natural
Fel d 1 tetramer (Fig 3, D).1,31 Their positions are consistent with
the design of the vaccine and presentation of the Fel d 1 protein on
the surface of the VLPs to B cells. Moreover, the epitopes are
located on an exposed face of the Fel d 1 tetramer, which is
compatible with binding and neutralization of the native allergen
Fel d 1.
Neutralization of Fel d 1 by vaccine-induced
antibodies
A competition ELISA was performed to assess whether the
vaccine-induced antibodies found in cat serum are capable of
neutralizing Fel d 1 (Fig 4,A). Both sera from immunized cats and
a Fel d 1–specific mAb were able to compete to the same extent
for binding to soluble Fel d 1 and prevented binding to the anti-
body coated on the ELISA plate, which resulted in a lower OD
value. In contrast, preimmune sera were not able to block binding.
FIG 4. Neutralizing ability of Fel d 1–specific antibodies induced in cats on Fel-CuMVTT vaccination. A,
Neutralization assay based on a capture ELISA to measure Fel d 1 protein. Recombinant (rec) Fel d 1 was
assayed either alone or mixed with preimmune (day 0) serum or postimmune (day 42) serum from a cat
immunized with 100 mg of Fel-CuMVTT on days 0 and 21, or 100 ng/mL anti–Fel d 1 mAb A044. OD values
at 450 nm are shown. P values were obtained by using a paired t test. B, Ear skin prick test. Mice received
anti–Fel d 1 IgE clones A044 and F127. Transfer of IgG-purified preimmune or postimmune serum from 2
cats enrolled to a Fel-CuMVTT immunogenicity study were performed. The control group received only
the anti–Fel d 1 IgE. Extravasation of Evan’s blue dye was quantified by using OD measurements at
595 nm. There were 3 mice in the control group. Mice tested with preimmune sera of 2 cats, n 5 6; mice
tested with postimmune sera of 2 cats, n 5 6. Significance was determined by using a 2-tailed Mann-
Whitney test.
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We further investigated the neutralization capacity of cat Fel
d 1–specific antibodies in vivo by using an ear prick test in mice
pretreated with Evan’s blue to visualize the local allergic reaction
(Fig 4, B).32 Control mice, which had not received cat serum, had
the highest level of local allergic reaction (Fig 4, B). Transfer of
preimmune cat serum somewhat decreased the reaction; however,
transfer of postimmune cat serum clearly reduced the degranula-
tion, indicating neutralization of Fel d 1 in vivo.
Taken together, Fel-CuMVTT vaccination induced highly spe-
cific Fel d 1 antibodies in cats exhibiting the ability to neutralize
Fel d 1.
Reduction of Fel d 1 levels in cat tears
Tears are one of the main sources of Fel d 1 and were therefore
analyzed for Fel d 1 levels upon vaccination with Fel-CuMVTT.
To perform the analysis of tears, we developed a method for col-
lecting and extracting tears. Tears were collected by using STT
stripes, extracted in PBS-Tween, and quantified for Fel d 1 levels
by means of ELISA in relation to a standard allergen solution.
A meta-analysis of 18 cats from 3 independent studies showed
a significant mean reduction of Fel d 1 level by a factor of 2.7
(Fig 5, A). In addition, one group of 4 cats was randomly selected,
and their tears were further analyzed (Fig 5, B-E).
The reduction in Fel d 1 levels of tear extracts of those 4 cats
measured by means of ELISA (Fig 5, B) was confirmed using a
second method based on a specially developed mass spectro-
metric analysis (Fig 5, C). For the analysis, a unique peptide,
ALPVVLENAR, of the major cat allergen Fel d 1, which was
located on chain 1, was identified. This sequence was then used
to synthetize a heavy peptide version bymodification of the C-ter-
minal arginine (R [13C6; 15N4]). The synthetic heavy peptide of
known concentration was spiked into the tear extracts and
compared with the light version of the peptide, which was present
in tears, as determined by using a combined LC/ESI/MS/MS (Fig
5, D).
In addition to quantification of Fel d 1 levels in tears, we also
assessed biological activity using a Basophil Activation Test.
Based on the quantitative analysis of Fel d 1 levels by means of
ELISA, dilutions of tear extracts were prepared containing
equivalent amounts of Fel d 1 and incubated with blood from
patients with cat allergy. Tear extracts collected after immuniza-
tion showed reduced reactivity compared with tear extracts
collected before immunization (Fig 5, E). This demonstrates
that vaccination with Fel-CuMVTT induced allergen-specific an-
tibodies in the cat that reduce levels of Fel d 1 in cat secretions
(tears) and its ability to elicit allergic reactions.
DISCUSSION
Here we demonstrate successful induction of Fel d 1–specific
antibodies in cats with the intent to reduce or prevent allergic
FIG 5. Reduction of Fel d 1 in cat tear extracts. Tears of immunized cats were collected by using STT stripes
and analyzed for Fel d 1 levels. A, Meta-analysis of Fel d 1 in tear extracts of 18 immunized cats from 3
different studies measured by using a quantitative ELISA (INDOOR Biotechnologies). Fel d 1 levels were
normalized tomilligrams of tears. Significancewas determined by using a 1-way ANOVA, followed by aWil-
coxonmatched-pairs signed-rank test. B,Measurement of Fel d 1 levels in tear extracts of a group of 4 cats in
a previous cat study. Fel d 1 amounts were normalized to milligrams of tears. P values were obtained by
using aWilcoxonmatched-pairs signed-rank test. C, Reduction of Fel d 1 levels in percentages in tear extract
solutions before (day 0) and after (day 42) immunization of 4 cats measured by means of ELISA or mass
spectrometry. Significance was determined by using a 2-tailed paired t test. D, Spectrum of the mass spec-
trometric analysis of light and heavy peptide ALPVVLENAR to quantify Fel d 1 in tear extract solutions
collected on day 0 or day 42. E, Basophil Activation Test assay was performed with blood from patients
with cat allergy mixed with tear extracts from cats from before (day 0) and after (day 42) immunization.
Tear extract solutions were diluted to the same Fel d 1 concentrations and tested to determine at which dilu-
tion 50% of basophil activation was achieved. The dilution of a certain Fel d 1 concentration that achieved
50% basophil activation was then related to the actual collected amount of the tear sample (milligrams of
tears to achieve 50% activation). Significance was obtained by using a paired t test.
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symptoms in human patients with cat allergy. Fel d 1 is a natural
and endogenous antigen in cats. Induction of an IgG response
against an endogenous protein requires an immunogenic agent
that can efficiently overcome B-cell and TH cell tolerance. Fel-
CuMVTT is designed to achieve this by means of repetitive
display of the antigen and delivering linked TH by the foreign
CuMVTT.
The vaccinewas tested in more than 50 cats to date and induced
a strong and sustained immune response against Fel d 1 in all
animals. No severe clinical signs, skin irritation at the site of
injection, or changes in food consumption or behavior were
observed. Minor signs, including increased temperature, loss of
appetite, or reduced activity, were reversible 24 to 72 hours after
immunization. Thus targeting Fel d 1 by means of induction of
antibodies through vaccination in cats was judged to be safe and
well tolerated. The immune responses against the self-protein Fel
d 1 and the foreign CuMVTT were comparable with regard to ki-
netics and magnitude.
We also tested a saponin-derived adjuvant to potentially
increase the specific antibody response. However, the adjuvant
only marginally increased antibody levels and also did not affect
the kinetics of the response; hence it will not be used in further
studies. This is an important point because the use of adjuvants is
associated to induce sarcoma in cats and are not normally
recommended to be used.42 The decrease in Fel d 1–specific
IgG levels occurred very slowly and titers could be maintained
by a booster injection. This indicates a strong B-cell activation
with sustained IgG antibody production, even in the absence of
an adjuvant.
Binding and neutralization of Fel d 1 by specific antibodies
might not be expected to result in toxic effects because they are
not likely to negatively affect Fel d 1 production per se or result in
its complete elimination. This assumption is further supported by
the fact that no essential biological role has been found for Fel d 1.
Moreover, Fel d 1 levels naturally vary greatly among cats (by
more than a factor of 100), and low levels of the molecule, as
observed in some neutered cats, are not associated with known
diseases.27,30 Because Fel d 1 is an endogenous protein to which
the cat is constantly exposed, it is unlikely to itself have any toxic
potential to the cat, particularly when administered in the context
of a vaccine.43
A potential toxicity resulting from formation of persistent
immune complexes comprised of natural Fel d 1 and specific
antibodies induced by vaccination and subsequent potential
activation of complement and effector cells, which might cause
inflammation and tissue damage is low. Fel d 1 is produced by
salivary, lacrimal, sebaceous, and perianal glands and is excreted
onto the external surfaces of the cat, which are the only known
sites of persistence.44 Fel d 1 has not been found in the circulation,
and hence the formation and deposition of immune complexes re-
sulting in activation of complement and effectors cells and subse-
quent inflammation are not considered likely. The possibility of
inducing autoreactive T cells is also considered unlikely because
of T-cell tolerance to soluble self-proteins.45 The T-cell help
required for induction of the anti–Fel d 1–induced B-cell response
is provided by the CuMVTT-VLP. Furthermore, by not including a
strong adjuvant in the vaccine formulation, the chances of acti-
vating tolerized or anergized potentially autoreactive T cells are
minimized. These considerations are supported by the fact that
no signs of toxicity have been seen in any of the more than 50
cats immunized thus far. Thus targeting Fel d 1 by induction of
antibodies through vaccination in cats can be judged to be safe
and well tolerated thus far. Nevertheless, further development
of the vaccine Fel-CuMVTT in cats will require a toxicologic
assessment by conducting a dedicated animal study.
The goal of vaccinating cats against Fel d 1 is induction of
specific antibodies capable of neutralizing themolecule in situ (ie,
in saliva or tears), rendering cats less allergenic to Fel d 1–sensi-
tive human subjects. The results presented herein provide evi-
dence that high-affinity Fel d 1 antibodies can be induced in
cats by means of vaccination and that these antibodies have the
ability to neutralize Fel d 1, as demonstrated by in vitro and in vivo
experiments, and also cause a decrease in active Fel d 1 levels in
tears, an important source of Fel d 1. Thus vaccination of cats with
Fel-CuMVTT can result in reduced symptoms of cat owners,
which would not only help the human but also help the cat
because of an improved relationship with the owner, which is a
new concept within movements like One Health (http://www.
onehealthinitiative.com).
We thank Dr Pal Johansen for scientific discussion and Boyd Jacobson for
the support of generating the graphical abstract.
Clinical implications: A possible alternative therapy of cat al-
lergy in human subjects is treatment of the cat by vaccination
against Fel d 1, the major cat allergen, to reduce its level in
cat secretions and its ability to induce an allergic reaction.
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